What Is Tirzepatide — and How Does It Compare to Semaglutide?

If semaglutide (Ozempic/Wegovy) was the medication that put GLP-1 drugs on the map, tirzepatide is the one that has the medical world genuinely excited. The clinical trial results for tirzepatide show weight loss numbers that were previously unachievable with any medical therapy short of surgery.

Here's what it is, how it differs, and what the science actually shows.

What Is Tirzepatide?

Tirzepatide is the active ingredient in two brand-name medications:

• Mounjaro — approved for type 2 diabetes management
• Zepbound — approved for chronic weight management

Like semaglutide, tirzepatide is a weekly injectable medication. Like semaglutide, it works partly through GLP-1 receptor activation.

But tirzepatide does something semaglutide doesn't.

The Key Difference: Dual Agonism

Semaglutide is a GLP-1 receptor agonist — it binds to and activates GLP-1 receptors.

Tirzepatide is a dual GIP and GLP-1 receptor agonist — it activates both GLP-1 receptors and GIP receptors simultaneously.

GIP stands for glucose-dependent insulinotropic polypeptide, another incretin hormone your body produces after eating. GIP works synergistically with GLP-1 to regulate blood sugar and — crucially — it also affects fat cells directly, influencing how your body stores and metabolizes fat.

The dual mechanism appears to produce more potent effects on both blood sugar and body weight than GLP-1 activation alone.

What the Clinical Trials Show

The SURMOUNT trials for tirzepatide (in the Zepbound formulation) showed:

• At the 5 mg dose: approximately 15% body weight reduction
• At the 10 mg dose: approximately 19.5% body weight reduction
• At the 15 mg dose: approximately 20.9% body weight reduction

The highest-responding quartile of patients in these trials lost over 25% of their body weight — approaching the results seen with bariatric surgery.

For comparison, semaglutide (Wegovy) trials showed approximately 15% average weight loss. Both numbers are far above what any previous weight loss medication achieved.

To be clear: individual results vary. These are averages from clinical trial populations. Some people respond dramatically; others respond less.

Head-to-Head Comparison

There has been a direct comparison trial (SURPASS-CVOT and related trials) comparing tirzepatide to semaglutide. In general, tirzepatide has shown greater average weight loss. Whether that difference matters for you personally depends on many factors.

| | Tirzepatide (Zepbound) | Semaglutide (Wegovy) |

|---|---|---|

| Receptor targets | GIP + GLP-1 | GLP-1 only |

| Average weight loss | ~20% | ~15% |

| Max dose | 15 mg/week | 2.4 mg/week |

| Injection frequency | Weekly | Weekly |

| Approval | 2023 (Zepbound) | 2021 (Wegovy) |

Side Effects and Contraindications

The side effect profile of tirzepatide is similar to semaglutide: primarily GI effects during dose escalation — nausea, vomiting, diarrhea, constipation. These are manageable for most people and tend to improve after the first few weeks at each dose.

The same contraindications apply: personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia type 2, pregnancy, or history of severe pancreatitis.

Which One Is Right for You?

This is a question for your physician, not for an article. Both medications are effective. The "right" one depends on:

• Your specific health history and conditions
• What your insurance covers
• How you tolerate the medication
• Your physician's clinical judgment based on your full picture

If you haven't tried either, the decision will be guided primarily by your health history and availability. If you've tried semaglutide and had limited response, tirzepatide may be a reasonable next option to discuss.

Ready to talk to a real doctor? Get started with Coral Health today.